Objective: To analyze nerve sparing performance at an early stage of robot-assisted radical prostatectomy, and the correlation between the surgeons' experience and the risk of a positive surgical margin in patients treated with robot-assisted radical prostatectomy. Methods: Patients' records from January 2009 to March 2013 were retrospectively reviewed, and 3469 patients with localized prostate cancer were identified at 45 institutions. Individual surgeon's experience with nerve sparing was recorded as the number of nerve sparing cases among total robot-assisted radical prostatectomies beginning with the first case during which nerve sparing was carried out. Patients were selected by propensity score matching for nerve sparing, and predictive factors of positive surgical margins were analyzed in patients with and without positive surgical margins. Results: A total of 152 surgeons were studied, and the median number of robotassisted radical prostatectomy cases for all surgeons was 21 (range 1-511). In all, 54 surgeons (35.5%) undertook nerve sparing during their first robot-assisted radical prostatectomy case. For 2388 patients selected with (1194) and without (1194) nerve sparing, predictive factors for positive surgical margin were high initial prostate-specific antigen level (P < 0.0001), high biopsy Gleason score (P = 0.0379), presence of neoadjuvant hormone therapy (P = 0.0002) and surgeon's experience with >100 cases (P = 0.0058). Thus, nerve sparing was not associated with positive surgical margins. Conclusion: The surgeon's experience influences the occurrence of positive surgical margins, although a considerable number of surgeons carried out nerve sparing during their early robot-assisted radical prostatectomy cases. Surgeons should consider their own experience and prostate cancer characteristics before carrying out a nerve sparing robot-assisted radical prostatectomy.
Introduction
RP is a definitive treatment for localized prostate cancer, with the aim of achieving radical cure. NS is also carried out to maintain QOL in some cases of RP, because RP decreases QOL owing to postoperative loss of erectile function and late recovery of continence. 1, 2 Previous reports suggest that NS could also increase the risk of a pSM. 3, 4 A pSM, in turn, might have a detrimental effect on biochemical recurrence-free survival and/or cancer-specific survival. [5] [6] [7] [8] [9] [10] Although NS is mostly carried out in consideration of patient conditions (e.g. age, erectile function, cancer risk), the basis of decision-making of whether to carry out NS differs among individual surgeons and institutions.
RARP has become a popular technique in recent years, although there is still controversy about the occurrence of the pSM in patients undergoing RARP when compared with an open procedure. [11] [12] [13] By any method, however, whether open, laparoscopic or robotic, RP has a significant learning curve that affects the pSM rate. 12, 14, 15 The surgeon's experience and expertise also affect the risk of a pSM, and should be taken into consideration. 16 The use of RARP is rapidly expanding worldwide, but it has not been clarified when novice surgeons should start carrying out NS or how the pSM rate changes according to their experience. In the present study, we analyzed the association of the individual surgeon's experience of carrying out NS with the risk of pSM during their early experience with RARP.
Methods Patients and data collection
The current study was undertaken with the approval and institutional oversight of each institutional ethics committee review board. Patients were retrospectively reviewed, and we identified 3469 patients with localized prostate cancer in 45 institutions from January 2009 to March 2013. Clinical and laboratory data of patients were collected from consecutive series in each institution and analyzed. Evaluation of the clinical stage and the decision to undertake NS were carried out with imaging in all cases. The procedures in the early cases of each institution were carried out under supervision of an invited expert according to the Japanese guideline and educational program for RARP. The individual surgeon's experience was recorded as the number of RARPs during which NS was carried out, beginning with the first RARP case in which NS was undertaken. The data were classified into five groups: ≤10, 11-20, 21-50, 51-100 and >100 cases depending on his or her total number of cases beginning at that point.
Statistical analysis
Because the patients' characteristics influence the decision about carrying out NS, the predicted probability of preprocedural stains for NS was calculated by fitting a logistic regression model, using preoperative and postoperative relevant variables, such as the surgeon's experience, body mass index, initial PSA level, clinical T stage, biopsy GS, presence of neoadjuvant hormone therapy, D'Amico risk score, pathological T stage and postoperative GS pathology report. Based on propensity score matching with a AE0.05 caliper, there were 1194 patients who underwent NS and 1194 who did not.
Among all patients and the selected patients, the characteristics and outcomes of patients were compared by the NS and surgical margin status using the v 2 -test for categorical variables, and the Student's t-test, Welch's t-test or Wilcoxon's ttest for continuous variables.
Multivariate logistic regression models incorporated the initial PSA level, clinical T stage, biopsy GS, presence of neoadjuvant hormone therapy, surgeon experience and performance of NS. Correlations between outcomes and assessed variables are expressed as the OR and 95% CI. Data were analyzed using JMP Pro version 9 software (SAS Institute, Cary, NC, USA). A value of P < 0.05 (two-sided) was considered to show statistical significance.
Results
A total of 152 surgeons at 45 institutions were studied. The median follow-up period after the procedure was 9 months (range 1-83 months). The median number of the surgeons' RARP cases was 21 (range 1-511). The median number of RARPs carried out before undertaking their first NS procedure during the RARP was 2 (range 1-30). In all, 54 surgeons (35.5%) undertook NS during their first RARP case. Overall, 10 (22.2%) of the 45 institutions had had no experience with NS during previous open/laparoscopic prostatectomies. The percentages of NS and pSM in these institutions were 27.8% (59/212) and 22.0% (13/59), respectively. In contrast, in the institutions that did have previous experience with NS, the percentages of NS and pSM were 41.7% (1357/3257) and 25.4% (345/1357), respectively. Thus, previous open/laparoscopic prostatectomy experience had the effect of carrying out the NS procedure more often (P < 0.001), but had no effect on the pSM rate (P = 0.5513) with RARP. Figure 1 shows the data for NS and surgical margins in each group categorized according to the surgeons' experience. 17 .3% (78/452), respectively. The pSM rates were significantly associated with the surgeon's experience -it was significantly lower in the group in which the surgeons had carried out >100 cases than in the other groups (P = 0.0002). Table 1 shows the patients' characteristics and outcomes, by NS status, for all patients and matched patients who were selected according to relevant variables. Among all patients divided by NS status, there were significant differences in their characteristics and operative data, with the exceptions of the SM status, body mass index and console time. Among the patients selected by propensity score matching, there were no significant differences between the NS and no-NS groups, except for age (P < 0.0001) and estimated blood loss (P < 0.0001).
We assessed the association of patients' characteristics and SM status in patients selected by propensity score matching (Table 2 ). In the univariate analysis, the patients with pSMs were at a high risk of prostate cancer, as shown by a high initial PSA level (P < 0.0001), clinical T stage (P = 0.0025), biopsy GS (P = 0.0289), D'Amico risk categories (P = 0.0003), pathological T stage (P < 0.0001) and pathological GS (P < 0.0001). The percentage of patients with extraprostatic extension and recurrence on the day of the surgery was higher in the pSM group (P < 0.0001). Surgeon's experience of >100 cases (P = 0.0115) and the presence of neoadjuvant hormone therapy (P = 0.0324) were associated with a lower pSM rate.
We assessed the predictive factors of pSM using multivariate logistic regression models, incorporating the patients' characteristics and the surgeons' experience (Table 3) . Predictive factors for pSM were the initial PSA level (OR 0.9560, 95% CI 0.9398-0.9722; P < 0.0001), biopsy GS (≥9 vs ≤6: OR 0.6124, 95% CI 0.3907-0.9725; P = 0.0379) and the use of neoadjuvant hormone therapy (yes vs no: OR 2.1252, 95% CI 1.4130-3.3112; P = 0.0002). The pSM rate was significantly lower in the patient group treated by surgeons with experience of >100 cases (>100 vs ≤10: OR 1.5852, 95% CI 1.1404-2.2308; P = 0.0058). The pSM rate did not differ significantly among the groups treated by surgeons with the experience of <100 cases (data not shown). Patients with ≥cT2c cancer tended to have a pSM (≥cT2c vs cT1: OR 0.7071, 95% CI 0.4998-1.0103; P = 0.0568). Regardless of whether the NS was unilateral or bilateral, the procedure was not associated with pSM (unilateral NS vs no NS: OR 1.0136, 95% CI 8263-1.2445; P = 0.8971; bilateral NS vs no NS: OR 0.8086, 95% CI 0.6016-1.0943; P = 0.1670).
Discussion
Although a pSM increases the risk of a biochemical recurrence after RP, there are different opinions on whether a pSM affects systemic progression and cancer-specific survival. 5, 6, 8, 9, [17] [18] [19] Some reports have shown that a pSM is an adverse predictor for biochemical recurrence, local recurrence, and development of metastasis and cancer-specific mortality. 9, 17 Other reports have suggested that pSMs alone are not associated with a significantly increased risk of systemic progression and cancer-specific survival. 18, 19 These series included patients who were treated with salvage radiotherapy and/or androgen deprivation therapy after biochemical recurrence. The most frequent reason why patients' survival was not affected by the presence of a pSM seems to be that they underwent salvage treatment after the biochemical recurrence. 18 In the present study, we were unable to identify an association of pSM with biochemical or clinical recurrence because of the short follow-up period. However, pSMs must increase the need for the salvage treatment, because the percentage of patients found to have a recurrence on the day of the surgery in the pSM group (5.1%, 46/902) was higher than that in the negative surgical margin group (1.08%, 27/2495). The presence of a pSM is associated with increased risk of biochemical recurrence and the need for salvage treatment.
The impact of the surgical approach on a pSM remains controversial. Previous reports have shown that the pSM rate is significantly lower in patients undergoing RARP than for those who undergo open RP. 11, 12, 20 In other reports, the pSM rate was similar for open RP, laparoscopic RP and RARP. 21, 22 According to the reports on open RP, pSM was significantly associated with the PSA level, clinical stage, biopsy GS, surgical technique and the surgeon's experience. 23, 24 For RARP, pSM was independently associated with the PSA level, PSA density, clinical stage, pathological stage, pathological GS and tumor volume. The pSM rate increases in patients with factors indicating a high risk of prostate cancer. 25 In the present study, high initial PSA level, high biopsy GS, absence of neoadjuvant hormone therapy and surgeon's lack of experience were factors predictive of pSM.
A previous report also showed that neoadjuvant therapy in patients undergoing RP significantly reduced the pSM rate. 26 Decreased tumor volume after hormone therapy might influence the risk of pSM in patients with neoadjuvant hormone therapy. Neoadjuvant therapy, however, does not improve overall survival or disease-free survival despite the improved pSM rate, so it is not always carried out. 27 Neoadjuvant therapy might help patients avoid salvage treatment, because it reduces the pSM. It also has the disadvantage, however, of being carried out on patients who do not need it. Further studies are required to clarify the application of neoadjuvant therapy for RP.
Preoperative underestimation of the clinical T stage and biopsy GS seems to affect decisions about carrying out NS and the causes of pSM. As shown in Tables 1 and 2 , incompatibility between the clinical and pathological T stage is reasonable, because histological evaluation covers the clinical stage of cT1 to the pathological stage of T2 or more. However, in 868 (62.0%) of 1401 patients without cT1 or after neoadjuvant therapy, the T stage was upgraded postoperatively. In particular, 28.5% (370/1297) of the cT2 patients were upgraded to pT3. Regarding the biopsy GS and the GS 4) †Surgeons' magnitude of experience is shown as the number of cases in which NS was carried out during RARP, beginning with the first case that the surgeon attempted NS during RARP. ‡Recurrence on operative day was defined as a PSA level that did not decrease under 0.1 after RARP.
found at the postoperative pathology evaluation, the percentage of upgraded and downgraded GS scores were 27.3% (803/2940) and 15.2% (446/2940), respectively (data not shown). Incompatibility between preoperative and postoperative factors, such as T stage or GS, might complicate the exact prediction of the risk of pSMs.
Previous reports have suggested that NS does not increase the risk of pSMs when patients are appropriately selected. In addition, the appearance of a pSM depends on the surgeon's technique and decisions. 3, 24, 25 The present data also showed that NS is not an independent predictor of pSM, regardless of whether the NS was lateral or bilateral. Although we did not evaluate the relationship between pSMs and the NS technique (e.g. intrafascial or interfascial incision), a recent review suggested that NS does not affect pSMs or compromise oncological outcomes. 28 The surgeon's experience and the state of the prostate cancer were predictors. A comparison of patients' characteristics by NS status in all patients (Table 1) showed that, although there was a higher rate of patients with a high risk of prostate cancer in the no-NS group than in the NS group, NS did not influence the pSM rate. The decision to carry out NS (or not) seems to be suitable in our series.
According to contemporary RARP series, the average rate of pSM is 15% (range 6.5-32.0%). In addition, the procedure has a significant learning curve that affects the pSM rate. 16, 29 When deciding whether to carry out NS, there are some important factors to consider, including the characteristics of the patient, the state of the prostate cancer and the patient's wishes, among others. It is not clear, however, whether surgeons take into consideration their own experience and The present study had some limitations. First, it was a retrospective study, and most of our patients were referred from other urological centers. Therefore, the procedures and evaluations, such as biopsy technique and image evaluation, were not standardized. Second, we did not have any information about the number of positive cores, tumor volume per tissue, NS techniques and prostate volume that might be factors influencing the appearance of a pSM. Third, we did not reassess the histological evaluation of GS and T stage by the central pathologist.
We showed the reality of undertaking NS, and the risk factors for pSM early in the surgeon's experience with RARP. The extent of the surgeon's experience was associated with the occurrence of a pSM, although a considerable number of surgeons carried out NS during their early cases. Surgeons should consider their own experience and the state of the prostate cancer before deciding to carry out NS.
